Stock Region Penny Picks
Stock Region Penny Picks Newsletter - Tuesday, December 3, 2024.
Stock Region Penny Picks Newsletter - Tuesday, December 3, 2024
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This newsletter is for informational purposes only and does not constitute financial advice. Always conduct your own research or consult a financial advisor before making any investment decisions.
$CHRS - Coherus BioSciences
Coherus has announced a significant agreement to divest its UDENYCA® franchise to Intas Pharmaceuticals Ltd. for up to $558 million. This move could streamline their operations and provide a strong influx of capital for future opportunities.
$CTNT - Cheetah Net Supply Chain Service
Cheetah Net is expanding its footprint with the acquisition of TW & EW Services. This strategic growth could enhance their operational capabilities and broaden their supply chain services, making them a company to monitor closely.
$ELVA - Electrovaya
Electrovaya received $4.1 million in purchase orders from a Fortune 500 customer to re-power two distribution centers. This is part of a broader fleet conversion strategy, with four additional centers being planned. A positive step for sustainable solutions in logistics.
$JFBR - Jeffs' Brands
Jeffs' Brands signed a binding letter of intent with Deliverz.AI for a U.S.-based joint venture. The partnership will focus on AI-powered, fully autonomous robots—an innovative move in the field of automation.
$ZENA - ZenaTech
ZenaTech's Spider Vision Sensors Ltd. has partnered on drone cameras compliant with Blue UAS and NDAA standards. This development could strengthen their standing in the U.S. defense sector.
$PSQH - PSQ
Big news for PSQ with Donald Trump Jr. and Willie Langston joining the board of directors. This addition has already drawn significant attention and aligns with the brand's "patriotic" marketplace mission.
$NLSP - NLS Pharmaceutics
Promising preclinical data from NLS Pharmaceutics highlights their dual orexin receptor agonists for the treatment of narcolepsy and neurological disorders. Investors may want to track their progress in these innovative treatments.
$ZJK - ZJK Industrial
ZJK Industrial is expanding its collaboration with NVIDIA into liquid cooling systems. With NVIDIA's leadership in tech innovation, this partnership could open up new opportunities for ZJK Industrial.
$TZUP - Thumzup
Thumzup has announced plans for a strategic integration with Elon Musk’s X Corp. (formerly Twitter). This could lead to exciting synergies in marketing and social engagement experiences.
$PALI - Palisade Bio
Palisade Bio's Phase 1 clinical study for PALI-2108 shows initial safety and tolerance as a treatment for moderate-to-severe ulcerative colitis. A positive early step in their development pipeline.
$GNLN - Greenlane
Greenlane signed an exclusive, multi-year global agreement to distribute CURB Lifestyle's breakthrough inhalation device technology. This could sharpen their edge in the wellness sector.
$ENLV - Enlivex
Enlivex reports positive interim data from its Allocetra trial for moderate to severe knee osteoarthritis—a potential breakthrough for patients with joint conditions.
$CTOR - Citius Oncology
Citius Oncology received a bullish rating from Maxim Group with a price target of $3. Investors will watch closely to see how this endorsement impacts trading activity.
$GWAV - Greenwave Technology Solutions
Greenwave is up 120% after acquiring real estate for seven of its core facilities. While specific terms were not disclosed, this acquisition strengthens their expansion strategy.
$AMZN - Amazon
Amazon Web Services (AWS) announced new database capabilities, including Aurora DSQL, and plans for an AI chip-powered computing system. Additionally, AWS entered a multi-year collaboration with Genpact. These moves reinforce AWS's technological dominance and continuous innovation.
$XAIR - Beyond Cancer
Beyond Cancer received approval from the Israeli Ministry of Health to conduct a Phase 1b clinical trial on nitric oxide therapy combined with anti-PD-1 treatments. This is a promising step in oncology research.
$CNEY - CN Energy
CN Energy has received an extension for the NASDAQ minimum bid price requirement, providing them additional time to align with listing standards.
Disclaimer: This newsletter is meant solely for information and should not be seen as an endorsement or recommendation of any stock. Stock trading carries risk, and past performance is not indicative of future results.
We are working endlessly to provide free insights on the stock market every day, and greatly appreciate those who are paid members supporting the development of the Stock Region mobile application. Stock Region offers daily stock and option signals, watchlists, earnings reports, technical and fundamental analysis reports, virtual meetings, learning opportunities, analyst upgrades and downgrades, catalyst reports, in-person events, and access to our private network of investors for paid members as an addition to being an early investor in Stock Region. We recommend all readers to urgently activate their membership before reaching full member capacity (500) to be eligible for the upcoming revenue distribution program. Memberships now available at https://stockregion.net